GBI Biomanufacturing Appoints Chandra Kelley as CBO

GBI Biomanufacturing Inc., a biologics Contract Development and Manufacturing Organization (CDMO), has appointed Chandra Kelley as Chief Business Officer (CBO). Kelley will lead the company’s commercial strategy, business development organization, client engagement initiatives, and long-term growth planning as the company continues to expand its capabilities and market presence.

“GBI Biomanufacturing is entering an exciting new phase of growth and capability expansion,” said Jesse McCool, President of GBI Biomanufacturing. “Chandra brings the client and market insights needed to deepen the way we support our early-stage antibody and ADC projects. Her experience structuring integrated and phase-appropriate work packages for rapid early phase supply aligns exceptionally well with GBI’s latest solutions in the mAb and bioconjugation space.”

Experience

Kelley brings more than 25 years of experience in the biotechnology and biopharmaceutical industry, with a track record of driving commercial growth, building strategic partnerships, and scaling customer-focused sales organizations across large molecule development and manufacturing services. Prior to joining GBI, she held senior commercial development roles at KBI Biopharma, Pfanstiehl, and SAFC.

“I’m excited to join GBI at such a dynamic stage of growth,” said Kelley. “I look forward to partnering with the team to further strengthen GBI’s position as a trusted CDMO partner supporting clients from development through commercialization.”